Table 1

Clinical features of the 69 SGMN patients
Male Female Total
% % %
Gender 28 40.6 41 59.4 69 100.00
Age ≤ 60 19 27.5 22 31.9 41 59.3
> 60 9 13.0 19 27.5 28 40.7
Smoking intake Yes 14 20.3 9 13.0 23 33.3
No 14 20.3 32 46.4 46 66.7
Alcohol intake Yes 9 13.0 5 7.2 14 20.3
No 19 27.5 36 52.2 55 70.3
Disease Classification MC 7 10.1 4 5.8 11 15.9
ACC 11 15.9 23 33.3 34 49.3
ACA 1 1.4 3 4.3 4 5.8
A.(nos) 4 5.8 1 1.4 5 7.2
BCA 2 2.9 3 4.3 5 7.2
PLGA 2 2.9 1 1.4 3 4.3
Cex-PA 0 0.0 4 5.8 4 5.8
SDC 1 1.4 2 2.9 3 4.3
PLSa PGb 10 14.5 17 24.6 26 37.7
SubM.Gc 8 11.6 5 7.2 13 18.8
SubL.Gd 0 0.0 2 2.9 2 2.9
MinorGe 10 14.5 17 24.6 27 39.1
Tumor Size T1 5 7.2 20 30.0 25 36.2
T2 12 17.4 5 7.2 17 24.6
T3 5 7.2 11 15.9 16 23.2
T4 6 8.7 5 7.2 11 15.9
Clinical Stage I 2 2.9 14 20.3 16 23.2
II 7 10.1 1 1.4 8 11.6
III 2 2.9 9 13.0 11 15.9
VI 17 24.6 17 24.6 34 49.3
Treatment Surgery 5 7.2 14 20.3 19 27.5
S. RT 11 15.9 19 27.5 30 43.5
S. CT. 3 4.3 1 1.4 4 5.8
S. RT and CT 9 13.0 7 10.1 16 23.2
Lymph node Negative 24 34.8 34 49.3 58 84.1
Positive 4 5.8 7 10.1 11 15.9
Metastasis No 15 21.7 28 40.6 43 62.3
Yes 13 18.8 13 18.8 26 37.7
Loco-regional No 17 24.6 28 40.6 45 65.2
recurrence Yes 11 15.9 13 18.8 24 34.8
Death No 15 21.7 33 47.8 48 69.6
Yes 13 18.8 8 11.6 21 30.4

RT: Radiotherapy; CT: Chemotherapy; a PLS: Primary Lesion Site; b PG: Parotid Gland; c SubM.G: Submandibular Gland; d SubL.G: Sublingual Gland; e MinorG: Minor Salivary Glands. MC: mucoepidermoid carcinoma; ACC: adenoid cystic carcinoma; ACA: acinic cell adenocarcinoma; A (nos): adenocarcinoma; Cex-PA: carcinoma ex-pleomorphic adenoma; SDC: salivary duct carcinoma; PLGA: polymorphous low-grade adenocarcinoma; BCA: basal cell adenocarcinoma (BCA); MMN: malignant myoepithelial neoplasm.

Soave et al.

Soave et al. Diagnostic Pathology 2013 8:29   doi:10.1186/1746-1596-8-29

Open Data